| Identification | Back Directory | [Name]
[TYR0] GASTRIC INHIBITORY PEPTIDE (23-42), HUMAN | [CAS]
121765-67-1 | [Synonyms]
[TYR0] GASTRIC INHIBITORY PEPTIDE (23-42), HUMAN
[Tyr22] Gastric Inhibitory Peptide (22-42), human
TYR-VAL-ASN-TRP-LEU-LEU-ALA-GLN-LYS-GLY-LYS-LYS-ASN-ASP-TRP-LYS-HIS-ASN-ILE-THR-GLN
[Tyr0] Gastric Inhibitory Peptide (23-42), human: [Tyr22] Gastric Inhibitory Peptide (22-42), human
TYR-VAL-ASN-TRP-LEU-LEU-ALA-GLN-LYS-GLY-LYS-LYS-ASN-ASP-TRP-LYS-HIS-ASN-ILE-THR-GLN: YVNWLLAQKGKKNDWKHNITQ | [Molecular Formula]
C119H182N34O31 | [MDL Number]
MFCD00167529 | [MOL File]
121765-67-1.mol | [Molecular Weight]
2584.93 |
| Hazard Information | Back Directory | [Uses]
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research[1][2]. | [in vivo]
GIPR-/- mice have higher blood glucose levels and impaired initial insulin response after oral glucose loading. In GIPR+/+ mice, a high-fat diet did not increase postprandial intake blood glucose levels, whereas it significantly increased in GIPR-/- mice[2].
| [References]
[1] LaPelusa A, et al. Biochemistry, Bombesin[M]//StatPearls [Internet]. StatPearls Publishing, 2021.
[2] K Miyawaki, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14843-7. DOI:10.1073/pnas.96.26.14843 |
|
|